Improving Visual Memory with Aricept (Donepezil Hydrochloride, E2020) in Mild-to-Moderate Alzheimer's Disease

Abstract Improving Visual Memory with Aricept (Donepezil Hydrochloride, E2020) in Mild-to-Moderate Alzheimer's Disease

[1]  A. Senning,et al.  Piracetam and other structurally related nootropics , 1994, Brain Research Reviews.

[2]  J. Colliver,et al.  Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. , 1998, Alzheimer disease and associated disorders.

[3]  L. Friedhoff,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study , 1998, European Neuropsychopharmacology.

[4]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[5]  T. Hadjistavropoulos,et al.  Primacy and recency effects in the assessment of memory using the Rey Auditory Verbal Learning Test. , 1992, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[6]  D. Kaufer.  Beyond the Cholinergic Hypothesis: The Effect of Metrifonate and Other Cholinesterase Inhibitors on Neuropsychiatric Symptoms in Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.

[7]  J. Cummings.  Metrifonate: Overview of Safety and Efficacy , 1998, Pharmacotherapy.

[8]  G. Stebbins,et al.  Effects of language disturbances on premorbid estimates of IQ in mild dementia. , 1990, The Clinical neuropsychologist.

[9]  J. Rogers,et al.  Direct Assessment of Activities of Daily Living in Alzheimer's Disease A Controlled Study , 1988, Journal of the American Geriatrics Society.

[10]  D. M. Parker,et al.  Estimation of Premorbid Intelligence in Organic Conditions , 1988, British Journal of Psychiatry.

[11]  S. Gray.  Advertisements for donepezil (Aricept) in the BMJ , 1997, British medical journal.

[12]  H. Beppu,et al.  Donepezil for mild and moderate Alzheimer's disease. , 2000 .

[13]  G. Stebbins,et al.  Use of the national adult reading test to estimate premorbid iq in dementia. , 1990, The Clinical neuropsychologist.

[14]  M. Weinstock,et al.  Selectivity of Cholinesterase Inhibition , 1999 .

[15]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[16]  R. Nebes,et al.  Sparing of semantic memory in Alzheimer's disease. , 1984, Journal of abnormal psychology.

[17]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[18]  P. Antuono.  Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. , 1995, Archives of internal medicine.

[19]  A. Awad,et al.  Psychopharmacology: The Fourth Generation of Progress , 1998, CNS Spectrums.

[20]  N. Varney,et al.  Psychopharmacology: The Fourth Generation of Progress. , 1996 .

[21]  Simon B. N. Thompson.  Dementia : a guide for health care professionals , 1997 .

[22]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[23]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[24]  B. Gulanski,et al.  Metrifonate treatment of the cognitive deficits of Alzheimer's disease , 1998, Neurology.

[25]  C. Gilleard,et al.  Estimation of premorbid intelligence in dementia. , 1986, The British journal of clinical psychology.

[26]  P. Aisen,et al.  SELEGILINE IN THE TREATMENT OF BEHAVIOURAL DISTURBANCE IN ALZHEIMER'S DISEASE , 1997, International journal of geriatric psychiatry.

[27]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[28]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[29]  C. Bouras,et al.  Neuroanatomic correlates of visual agnosia in Alzheimer’s disease , 1999, Neurology.

[30]  I. McKeith.  The Clinical Trial Protocol of the Metrifonate in ALzheimer’s Trial (MALT) , 1998, Dementia and Geriatric Cognitive Disorders.

[31]  A. Burns,et al.  New drugs for Alzheimer's disease , 1999, British Journal of Psychiatry.

[32]  M. Mélac,et al.  Drug Therapy and Memory Training Programs: A Double-Blind Randomized Trial of General Practice Patients With Age-Associated Memory Impairment , 1994, International Psychogeriatrics.

[33]  M. Swash,et al.  Assessing intellectual deterioration. , 1986, The British journal of clinical psychology.

[34]  J. Whittick,et al.  Does the National Adult Reading Test hold in dementia? , 1987, The British journal of clinical psychology.

[35]  W. Deberdt,et al.  Interaction between psychological and pharmacological treatment in cognitive impairment. , 1994, Life sciences.

[36]  P. Tariot.  Evaluating response to metrifonate. , 1998, The Journal of clinical psychiatry.

[37]  A Whitehead,et al.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.

[38]  M. Freedman,et al.  L-deprenyl in Alzheimer's disease , 1998, Neurology.

[39]  D. Bub,et al.  Object identification deficits in dementia of the Alzheimer type: Combined effects of semantic and visual proximity , 1999, Journal of the International Neuropsychological Society.

[40]  S. Gray,et al.  Donepezil Use in Alzheimer Disease , 1998, The Annals of pharmacotherapy.

[41]  C. Mondadori.  Nootropics: preclinical results in the light of clinical effects; comparison with tacrine. , 1996, Critical reviews in neurobiology.